Stressgen (VSE: SSB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: William Marsh who wrote (119)	5/22/2000 5:30:00 PM
From: Heat Shock	Read Replies (1) of 236

To all: Stressgen's ASCO data: StressGen Reports Fusion Protein Drug for Human Papillomavirus Demonstrated Positive Immune Responses and is Well Tolerated in Phase I Study -- Data Presented at Annual Meeting of American Society of Clinical Oncology -- biz.yahoo.com The holy grail of cancer vaccines is to illicit killer T cell activity, and that was one of the end points of the study. Great result: the drug, HspE7 (SGN-00101), was also found to activate T-cells, a critical marker for immunological activity. Things are on track. Heat

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next